Industry Reports
The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
The ultimate guide to the complex web of interactions within the U.S. prescription distribution and reimbursement system more >
The 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
The most comprehensive tool for analyzing the economic and business realities of the U.S. pharmaceutical distribution industry. more >
From The Drug Channels Blog
Friday, July 10, 2026
When Access Tightens, Prior Authorization Execution Becomes the Differentiator
Today's guest post comes from Megan Wetzel, Vice President of Product, Access and Affordability at CoverMyMeds. Megan examines how prior authorization execution has become a strategic differentiator for biopharma more >
Wednesday, July 8, 2026
The Hidden Cost of 340B for Employers and Health Plans
By Adam J. Fein, Ph.D.For years, the controversy surrounding the 340B Drug Pricing Program has centered on hospitals, manufacturers, and contract pharmacies. But employers and health plans more >
